As well as a wealth of in-house expertise, we have a range of partners to ensure we remain at the forefront of point of care diagnostics.

We believe that a diversity of knowledge and perspectives will support the success of the company and our products.

We partner with

We work with a number of NGOs to develop tools and technologies suited to healthcare settings of all resource levels, and to ensure our products have a significant societal impact.

Assay Developers

In order to expand our Q-POC™ testing menu, we co-develop assays with academic, commercial and non-profit partners. This enables us to access expertise in a range of fields.

Academic Institutions

We strategically partner with academic institutions to deliver the best possible assays, with development informed by the most up-to-date innovative research.

Life Sciences

We’re in discussions with a number of life science multinationals in order to out-license component technologies and realise their potential across the globe.

Applied Markets

The inherent flexibility of our technologies, particularly our sample preparation, means they can provide solutions to problems in a range of fields, from agriculture to environmental monitoring, from bioterror to oil & gas, from veterinary to food safety.

Pharmaceutical Companies

We are frequently approached by pharmaceutical companies interested in a companion diagnostic test to provide crucial information on drug sensitivity, dosage, or side effects in minutes by the patient’s side.

Global partnerships support our global strategy

Find out how we’re working with partners


Global partnerships support our global strategy

Find out how we’re working with partners

Successful partnerships with experts in the fields of tuberculosis and HPV diagnostics have been crucial to the development of these assays and the Q-POC™ device itself.

Collaborations have provided insight into the end users and the environments in which testing will be carried out; they’ve provided samples for test development; they’ve informed selection of the biomarkers included in the assay.

We are keen to continue with this effective model for the development of the following tests:

  • sexually transmitted infections
  • neglected tropical diseases
  • HIV, particularly early infant diagnosis

Further information on key areas of interest can be found in our Applications area.

If we have some common interests and you feel there may be scope for a possible collaboration,
please get in Contact with us.


Our key areas of interest can be found in our Applications area.

Subscribe to our e-newsletter and keep up to date with QuantuMDx